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Abstract
This population-based study describes the survival of patients with cancer of
the oral cavity, diagnosed from 1994 to 2013 in Finland, followed up through
2014. The life table method and the relative survival framework are used to
estimate net survival for the cancer patients under study. Two recommended
estimators, the Ederer II and the Pohar Perme, for net survival are compared.
The material used in this thesis is from the Finnish Cancer Registry and
consists of 4211 cancer cases. 201 cancer cases were diagnosed only in autopsy
and were excluded from the analyses, leaving 4010 observations that were used
for the survival analysis.
Survival curves are presented for observed and relative survival estimates.
Analyses were stratified by sex, patients’ age, stage of cancer and calendar
year at the time of diagnosis.
Patient’s age and stage of cancer turned out to be important predictors of
patient survival from this cancer, which was expected from literature. The
study period was divided into two ten-year calendar periods by the calendar
years of diagnoses. There was not a clear difference between the survival of
these periods.
The Ederer II and the Pohar Perme estimators of net survival performed
similarly when a large quantity of data was available, e.g. when estimating
the five-year relative survival ratio for cancer of the oral cavity. Estimates
differed when less data were available, e.g. when the relative survival ratio for
longer follow-up periods was estimated or when the analysis was stratified by
age and patients in the older age groups were considered. In these situations
the standard error of the Pohar Perme estimator was considerably larger than
the standard error of the Ederer II estimator.
1
Tiivistelmä
Tässä väestöpohjaisessa tutkielmassa kuvaillaan suuontelon syöpäpoti-
laiden elinaikoja. Potilaat on diagnosoitu Suomessa vuosien 1994-2013
aikana ja heitä on seurattu vuoden 2014 loppuun. Tutkielmassa käytetään
aktuaarimenetelmää ja suhteellista elossaololukua suuontelon syövän
nettoelossaolon estimoimiseksi. Kahta suositeltua menetelmää, Ederer II ja
Pohar Perme, verrattiin nettoelossaolon estimoimiseksi.
Tutkielmassa käytetty aineisto on Suomen Syöpärekisteriltä. Aineisto koos-
tuu 4211:stä syöpäpotilaasta. Potilaista 201:llä oli todettu suuontelonsyöpä
vasta ruumiinavauksessa, joten heidät poissuljettiin analyysista. Analyyseissa
käytettävän aineiston koko oli lopulta 4010 potilasta.
Havaitun ja suhteellisen elossaolon estimaatit on esitelty välttökäyrien ja
kiinnostavien tunnuslukujen avulla. Analyyseissä on käytetty osittavina
tekijöinä sukupuolta, potilaan ikää, syövän levinneisyyttä ja kalenterivuotta
diagnoosihetkellä. Vertailut tehdään kuvailevasti esitetyistä välttökäyristä ja
taulukoiduista tunnusluvuista.
Potilaan ikä ja syövän levinneisyys ovat tärkeitä ennustetekijöitä, jotka vaikut-
tivat merkittävästi suuontelon syöpäpotilaan elinaikaan, mikä oli odotettavissa
kirjallisuuden perusteella. Tutkimusjakso on jaettu kahteen kymmenvuotisjak-
soon diagnoosivuosien perusteella. Jaksojen välillä ei ollut nähtävissä selvää
eroa elinajoissa.
Nettoelossaolon Ederer II ja Pohar Perme -estimaatit olivat samansuu-
ruisia, kun käytettävissä oli paljon aineistoa, esimerkiksi laskettaessa viiden
vuoden suhteellista elossaoloa. Erot tulivat esiin kun käytettävissä oli
vähemmän aineistoa, esimerkiksi laskettaessa suhteellista elossaoloa pitkille
seuranta-ajoille tai iän mukaan ositetussa analyysissa vanhoilla ikäryh-
millä. Kun aineistoa oli vähän, Pohar Perme -estimaatin keskivirhe kasvoi
huomattavasti suuremmaksi kuin Ederer II -estimaatin keskivirhe.
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1 Introduction
In population-based cancer survival studies, estimating net survival is a com-
mon practice. Net survival is used when the interest is the probability that a
patient will die of a specific cause. Net survival cannot be estimated directly
from the survival times of patients, thus a relative survival framework is com-
monly used. (Dickman and Coviello 2015; Rebolj Kodre and Pohar Perme
2013) Estimating net survival in a population-based setting with relative sur-
vival estimators is the key subject of this thesis.
Cancer of the oral cavity, together with cancer of the lip, is one of the more
common of head and neck cancers in Finland. Common risk factors for this
cancer are smoking and heavy alcohol use, separately causing a sixfold increase
in the hazard of cancer and together increasing the hazard of cancer up to 15
times higher. Typically patients with cancer of the oral cavity are over 60
years old, but little over 10 % of patients are diagnosed before they are 40
years old. The cancer of the oral cavity tends to be quite agressive and can
spread to metastases quite fast, sometimes a lump in the neck can even be
the first symptom. Around 30 % of patients are diagnosed with metastases in
the neck area, but metastases elsewhere in the body are rare. (Joensuu et al.
2013)
Patients diagnosed with a small tumor can have an expected five-year survival
proportion up to 90 %, while for patients diagnosed with a large tumor it can
be as low as 20 %. Furthermore, the five-year survival proportion is generally
halved for patients who are diagnosed with a cancer that has spread to a
metastasis on the same side of the neck, and reduced to a quarter for patients
diagnosed with bilateral metastases, compared to those with local tumor. After
a local recurrence or a discovery of metastasis, getting a curative treatment
outcome is rare, and on average patients have a life expectancy less than one
year. (Joensuu et al. 2013)
In Section 2 the methods of survival analysis are introduced. The focus is on
the survival and the net survival functions, and their estimators. In Section
3 the material used in this thesis is described. In Section 4 the baseline char-
acteristics of the cancer patients in the study population are presented first,
then the results of survival analyses are presented. Finally The Ederer II and
the Pohar Perme estimators of net survival are compared. Lastly in Section 5
the concept of net survival and results of the survival analyses are discussed.
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2 Methods
In this chapter the characteristics of survival data and the methods of survival
analysis are presented. Methods used in this thesis are focused. At the end of
this chapter, the computational tools used to produce the results of this thesis
are described.
2.1 Characteristics of survival data
Survival analysis is the analysis of data in the form of times from a well-
defined time origin until an interesting end-point. In the medical field the
end-point is often the occurence of a particular event, e.g. death, while the time
origin corresponds to the recruitment of an individual into a study, commonly
coinciding with the diagnosis of the particular condition. If the end-point is
not fatal, observations can be referred to as time to event data.(Collett 2015)
Censoring is the main feature that renders standard data analysis methods
inappropriate. Survival data are said to be censored when the interesting end-
point is not observed. In this thesis, only right censoring is considered, which
occurs after an individual has entered the study, to the right of the last known
survival time. From now on it will be referred to as censoring. For more about
different censoring processes see e.g. Leung, Elashoff, and Afifi (1997) and
Collett (2015).
An individual is lost to follow-up, if they could not be reached for a check up,
e.g. because emigration, and the only information available is the last day they
are known to be alive. Administrative censoring happens when the observation
period of a study ends or the data are analysed before the observation period
ends, thus some of the patiens might be alive. (Leung, Elashoff, and Afifi 1997;
Collett 2015)
Nonetheless, an individual enters the study at a time t0 and dies at a time
t0 + t, but the time t is unknown. If the interesting end-point is not observed,
but a patient was last known to be alive at a time t0 + c, the time c is called a
censored survival time. Most survival analysis methods require an assumption
of independent censoring, to include censored survival times. This means that
a time t must not be dependent on any mechanism that causes a survival time
to be censored at a time c, where c < t. When the assumption is true, an
individual is representative of all other individuals who have survived until
the time c. (Collett 2015; Leung, Elashoff, and Afifi 1997)
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The recruitment period of a study can extend over days, months or even years.
This causes calendar time periods of individuals in the study, study times, to
differ. The study begins for an individual when they are recruited at their
time origin t0, and in the medical field the period of time they spend in the
study is often called patient time. (Collett 2015)
2.2 Survival, hazard and cumulative hazard functions
In this section the survival function, the hazard function and the cumulative
hazard function are introduced. They are commonly used to describe the dis-
tribution of survival times. Some useful relationships between these functions
are also derived. The theory in this sections is adopted from Collett (2015),
Seppä (2012) and Seppä et al. (2016).
Let T be a random variable describing survival time and t be any fixed survival
time, i.e. a possible realised value of T . Clearly t can only have non-negative
values. Now, suppose T has some underlying probability density function f(t),
then the cumulative distribution function of T is
F (t) = P (T ≤ t) =
∫ t
0
f(u)du. (1)
This function is sometimes called the cumulative incidence function, because
it describes the cumulative probability of the interesting end-point occuring
before the time t.
Now, the survival function S(t), is defined as the probability of the survival
time being greater than t:
S(t) = P (T > t) = 1− F (t). (2)
An alternative presentation for the survival funtion is
S(t) = P (T > t) = exp
{
−
∫ t
0
h(u)du.
}
, (3)
where h(t) is the hazard function:
h(t) = lim
∆t→0
P (t < T ≤ t+ ∆t | T > t)
∆t . (4)
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The hazard function is interpreted as the instantaneous rate at which death
occurs, having not occurred before. The considered probability is that the
random variable T lies between times t and t+ ∆t, conditional on the survival
time, T , being greater than t. The hazard function is then defined as the
limiting value of this probability, divided by the time interval ∆t, when the
interval tends to zero.
If the hazard can be assumed constant over a short time period, say ∆t, the
expected number of events experienced in an unit time is h(t)×∆t, given the
event has not occurred before.
The cumulative hazard, H(t), is given as
H(t) =
∫ t
0
h(u)du. (5)
The cumulative hazard function summarises the hazard of an event of interest
up to a time t, given the event has not occurred before. It is possible for the
cumulative hazard function to exceed unity, which means that the expected
number of events is greater than one in the time interval (0, t). The interpre-
tation that the cumulative hazard function is the expected number of events in
a time interval is only reasonable if a repetition of an event is possible, e.g. an
occurence of an infection or backpain.
Some useful relationships can be obtained between these functions. Note that
the probability of an event A, given that an event B occurs, is P (A|B) =
P (A ∩ B)/P (B), where P (A ∩ B) is the probability of the joint occurence of
A and B. With this result, the probability in the Equation 4 can be written
as
P (t < T ≤ t+ ∆t)
P (T > t) ,
which is
F (t+ ∆t)− F (t)
S(t) ,
where F (t) is the distribution function of T given in the Equation 1. Now, the
hazard function can be written as
h(t) = lim
∆t→0
{
F (t+ ∆t)− F (t)
∆t
}
1
S(t) ,
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where
lim
∆t→0
{
F (t+ ∆t)− F (t)
∆t
}
= F ′(t) = f(t)
is the density function of T . Thus,
h(t) = f(t)
S(t) . (6)
Also, the Equation 3 can be written as
S(t) = exp {−H(t)}, (7)
then we get
H(t) = − log S(t). (8)
and
h(t) = − ddt log S(t). (9)
There are multiple ways to determine any of the presented functions. From
any one of the four functions f(t), S(t), h(t) and H(t), the other three can be
determined.
Considering these functions on an individual level, let Ti be a random variable
representing the survival time of an individual i. The survival probability of
an individual i is defined as
Si(t) = P (Ti > t) = exp
{
−
∫ t
0
hi(u)du.
}
,
where hi(t) is the hazard of an individual i:
hi(t) = lim
∆t→0
P (t < Ti ≤ t+ ∆t | Ti > t)
∆t .
In a group on n individuals, the overall survival is the mean of the survival
probabilities of the individuals in the group:
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S(t) = 1
n
n∑
i=1
Si(t).
2.3 Net and relative survival
In this section net survival and relative survival, the latter as an estimate for
net survival, are considered along with the concept of competing risks. The
theory in this section is based on Seppä (2012) and Seppä et al. (2016).
Multiple causes of death are often present when survival data are analysed,
though the interest usually is focused on a particular cause of death, e.g. can-
cer. Let C be a random variable related to the cause of death. The cause-
specific hazard, hc(t), is defined as the instantaneous rate at which death occurs
due to the cause C = c, given that death from any cause has not occurred
before:
hc(t) = lim
∆t→0
P(t < T ≤ t+ ∆t ∩ C = c | T > t)
∆t (10)
Given that different causes of death are mutually exclusive, the sum of the
cause-specific hazards is equal to the overall hazard. For example, if C =
{1, 2}, then h(t) = h1(t) + h2(t).
When different competing risks of death are present, the cause-specific cumu-
lative incidence function from the time of diagnosis to a time t is
Fc(t) = P(T ≤ t ∩ C = c) =
∫ t
0
hc(u)S(u)du.
Again, let Ti be a random variable representing the survival time of an indi-
vidual i until death from any cause. Introducing the concept of competing
risk to this variable, suppose Ti is the minimum of two random variables,
min {TEi , T Vi }. Now, TEi is the time to death from a given cancer, and T Vi
is the time to death from other causes than the cancer. Only one of these
survival times can be observed for each individual. If the competing risks are
mutually independent, the net survival function could be defined as the sur-
vival probability of an individual i, in the absence of other causes of death,
i.e. the hypothetical situation where other causes of death than cancer are
eliminated:
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SEi(t) = P(TEi > t) = exp
{
−
∫ t
0
hEi(u)du
}
,
where hEi(t) is the net hazard of the ith individual:
hEi(t) = lim
∆t→0
P(t < TEi ≤ t+ ∆t | TEi > t)
∆t .
In a group of n patients, the overall net survival is the mean of the net survival
probabilities of the individuals in the group:
SE(t) =
1
n
n∑
i=1
SEi(t). (11)
Additionally, if TEi and T Vi can be assumed to be independent:
S(t) = SE(t)× SV (t).
Thus the interesting net survival SE(t) could be estimated based on the overall
survival S(t) and the net survival SV (t). The latter refers to the hypothetical
situation where deaths due to the interesting cancer are eliminated.
The probability interpretation of net survival requires the assumption about
the independence of competing risks to be true. This assumption should be
taken with a caution, since it can rarely be verified through data. From the
Equation 11, the observable net survival can be defined by replacing the net
hazard of an individual i, hEi(t), with the observed excess hazard of said
individual
h∗Ei(t) = lim∆t→0
P(t < TEi ≤ t+ ∆t | Ti > t)
∆t .
Relative survival offers a method for estimating net survival, even when the
causes of death are unknown or assumed to be unreliable. The net survival
if deaths due to cancer were eliminated, SV (t), is estimated by the expected
survival function SP (t), that refers to the survival of a group, that is free of
cancer, in a relevant reference population similar enough with the group under
study, in terms of traits affecting mortality.
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Expected survival can be estimated from a large national population. When
stratified by sex, age and calendar year, the expected survival can be con-
sidered fixed, or basically free from random error. A reference population of
a large nation obviously also contains cancer cases of the interest, and pos-
sibly includes individuals who are under study. This effect can be assumed
negligible on the estimated relative survival of a large national population.
As stated before, if the assumption of the independence of TEi and T Vi is in-
valid, the net survival has no meaningful probability interpretation. However,
the relative survival ratio can always be interpreted as the ratio between the
corresponding probabilities of an individual under study, and a healthy indi-
vidual in the reference population, being alive at a time t, i.e. the ratio between
observed and expected survival:
SR(t) =
S(t)
SP (t)
.
Furthermore, the excess hazard can be used as a surrogate estimate for the net
hazard. It is the excess rate of death an individual with cancer has, compared
to the rate of death in a comparable healthy person, hP (t):
hR(t) = h(t)− hP (t).
In a group of n individuals, the relative survival ratio is defined as the ratio
between the averages of the observed and the expected patient-specific survival
probabilities:
SR(t) =
∑n
i=1 Si(t)∑n
i=1 SPi(t)
. (12)
However, in a group of n individuals the net survival is the average of the
patient-specific net survival probabilities SEi(t) as defined in the Equation 11.
Now, the net survival of an individual i can be written as the ratio between
the observed and the expected survival of said individual:
SE(t) =
1
n
n∑
i=1
SEi(t) =
1
n
n∑
i=1
Si(t)
SPi(t)
. (13)
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2.4 Life table estimators
In this section the life table method, and estimators for the survival function,
the hazard function and the cumulative hazard function based on it are pre-
sented. The theory in this section is based on Collett (2015), Gehan (1969),
Seppä (2012) and Seppä et al. (2016).
Two popular non-parametric approaches to estimating the survival function
are the Kaplan-Meier method and the life table method. The latter is preferred
in this thesis, since exact survival times must be observed to use the Kaplan-
Meier estimates, and the population-based survival data used in this thesis
does not have the exact dates. Also in such cases when the exact survival
times are known, life table estimates can still be used, but might lead to some
loss of information. Alternative methods, such as the Kaplan-Meier, are then
more appropriate, see e.g. Collett (2015).
In the life table method, sometimes also called the actuarial method, the sur-
vival data are grouped by dividing the period of observation into a series of
disjoint time intervals. These intervals need not to be of same length, and the
number of intervals can depend on the number of individuals in the study.
Consider the jth of such J intervals: [tj−1, tj), j = 1, 2, . . . , J , where t0 = 0
and tJ =∞. Let nj be the number of individuals alive and under follow-up at
the start of the jth interval, thus being at risk of death. Let dj be the number
of deaths and cj be the number of individuals with a censored survival time in
the interval j. The actuarial assumption, is that censoring happens uniformly
throughout the jth interval and independently of death, i.e. individuals with
a censored survival time are assumed to be at risk of dying for half of the
duration of the interval, on the average. The average number of individuals
at risk during the jth interval, i.e. the effective denominator, is
n′j = nj −
cj
2 . (14)
The estimated probability of death in the jth interval is q̂j = dj/n′j, and the
estimated survival probability over the interval is
p̂j = 1− q̂j =
n′j − dj
n′j
. (15)
If there are no censored survival times, the survival function S(t), defined in
the Equation 2, is simply estimated by the empirical survival function:
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S̃(t) = 1− F̃ (t) = Number of individuals with a survival time ≥ tNumber of individuals in the data , (16)
where F̃ (t) is the empirical distribution function, i.e. the ratio of individuals
alive at a time t to the total number of individuals. S̃(t) is unity for the values
of t before the first observed death time and zero after the last observed death
time, and it is assumed to be constant between adjacent death times.
When there are censored survival times, the probability that an individual
survives beyond a time tj−1, j = 1, 2, . . . , J , i.e. beyond the start of the jth
interval, is the product of the conditional probabilities that an individual sur-
vives through all the preceding j − 1 intervals. The life table estimate of the
survival function is then
Ŝ(t) =
k∏
j=1
(
n′j − dj
n′j
)
=
k∏
j=1
(1− q̂j) =
k∏
j=1
p̂j, (17)
for tj−1 ≤ t < tj, j = 1, 2, . . . , J. The probability of surviving beyond the start
of the first interval, t0, is unity, while the probability of surviving beyond tJ is
zero.
The hazard function is defined in the Equation 4. To estimate it, a constant
death rate is assumed during the jth interval. An appropriate estimate of
the average hazard of death per unit time, is the observed deaths divided by
the average time survived, in the jth interval. Assuming the constant death
rate, the average time survived during an interval is (n′j − dj/2)τj, where τj
is the length of the jth interval. The estimated hazard function, ĥ(t), is a
step-function over the observation period, and in the jth interval estimated by
ĥ(t) = 2q̂j(1− p̂j)τj
= dj(n′j − dj/2)τj
, (18)
for tj−1 ≤ t < tj, j = 1, 2, . . . , J .
The cumulative hazard at a time t, H(t), is defined in the Equation 5 to
be the hazard function integrated until t. However, it is more convenient
to find the cumulative hazard function using the Equation 8. Ŝ(t), given in
the Equation 17, is the life table estimate of the survival function and an
appropriate estimate of the cumulative hazard function is
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Ĥ(t) = − log Ŝ(t),
for tj−1 ≤ t < tj, j = 1, 2, . . . , J . Since the derivative of the cumulative
hazard function is the hazard function, the slope of the cumulative hazard
function provides information about the underlying hazard function. e.g. a
linear cumulative hazard function over some time interval suggests that the
hazard would be constant over that interval (Collett 2015).
2.5 Standard error and confidence interval
This section considers the standard error and the confidence interval of the
life table estimator of the survival function. For the derivation of the standard
error of the life table estimate of the hazard function, see Gehan (1969). The
theory in this section is based on Collett (2015), Gehan (1969), Seppä (2012)
and Seppä et al. (2016).
To derive the standard error of the survival function, we start by taking loga-
rithms in the Equation 17
log Ŝ(t) =
k∑
j=1
log p̂j,
and the variance of log Ŝ(t) is
var
{
log Ŝ(t)
}
=
k∑
j=1
var{log p̂j}. (19)
Now, a binomial distribution is assumed for the individuals who survive
through the interval j. The binomial distribution takes parameters n′j
and pj, where the latter is the true probability to survive through the jth
interval. Using the result that the variance of a binomial random variable
with parameters n and p is np(1− p), the variance of the observed number of
individuals who survive through the jth interval, n′j − dj, is
var(n′j − dj) = n′jpj(1− pj).
From the Equation 15
15
var (p̂j) =
var(n′j − dj)
(n′j)2
= pj(1− pj)
n′j
.
Thus, the variance of p̂j is estimated by
v̂ar (p̂j) =
p̂j(1− p̂j)
n′j
. (20)
To obtain the variance of log p̂j, we use the general result that the approximate
variance of a funtion g(X) of the random variable X is
var{g(X)} ≈
{
dg(X)
dX
}2
var(X). (21)
This is known as the Taylor series approximation of the variance of a function
of a random variable. With the Equation 21:
var (log p̂j) ≈
var(p̂j)
p̂2j
.
Then, with the Equation 20, and a substitution for p̂j:
v̂ar (log p̂j) ≈
1− p̂j
n′j p̂j
= dj
n′j(n′j − dj)
. (22)
Applying this to the Equation 19
v̂ar
{
log Ŝ(t)
}
≈
k∑
j=1
dj
n′j(n′j − dj)
, (23)
and further applying the result in the Equation 21:
v̂ar
{
log Ŝ(t)
}
≈ 1[
Ŝ(t)
]2var {Ŝ(t)} .
So the approximated variance of the survival function is
v̂ar
{
Ŝ(t)
}
≈
[
Ŝ(t)
]2 k∑
j=1
dj
n′j(n′j − dj)
. (24)
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The standard error is defined as the square root of the variance of the estimate,
so the approximated standard error of the life table estimate of the survival
function is
se
{
Ŝ(t)
}
≈ Ŝ(t)

k∑
j=1
dj
n′j(n′j − dj)

1
2
, (25)
for tj−1 ≤ t < tj. This result is known as the Greenwood’s formula.
If there is no censored survival times in the sample, i.e. nj+1 = nj − dj, the
Equation 22 can be reduced:
v̂ar (log p̃j) ≈
nj − nj+1
njnj+1
,
and
var
{
log S̃(t)
}
≈
k∑
j=1
nj − nj+1
njnj+1
=
k∑
j+1
(
1
nj+1
− 1
nj
)
= n1 − nk+1
n1nk+1
. (26)
Since S̃(t) = nk+1/n1 for tj−1 ≤ t < tj, j = 1, 2, . . . , J , in the absence of
censoring, the Equation 26 can be written as
1− S̃(t)
n1S̃(t)
.
Thus, from the Equation 24
v̂ar
{
S̃(t)
}
≈
S̃(t)
[
1− S̃(t)
]
n1
.
This is an estimate for the variance of the empirical survival function in the
Equation 16, assuming the number of individuals at risk at a time t has a
binomial distribution with parameters n1, S(t).
A confidence interval (CI) is an interval estimate, with a prescribed probability
that the true value of the estimate is covered by the random interval. The
presented intervals are pointwise confidence intervals, since they refer to a
specific time point, and can be found at any given time t. Assuming the
estimated value of the survival function, at a given time t, to be normally
distributed with a mean S(t), and an estimated variance given by the Equation
17
24, a confidence interval for the true value of the survival function S(t) at
a time t can be computed from percentage points of the standard normal
distribution.
Now, if Z is a random variable with a stardard normal distribution, the upper
(one-sided) α/2-point of the distribution is the value zα/2, such that P(Z >
zα/2) = α/2. Then a 100(1−α)% approximate confidence interval for S(t), for
a given value of t, is the interval[
Ŝ(t)− zα/2 × se{Ŝ(t)}, Ŝ(t) + zα/2 × se{Ŝ(t)}
]
,
where se{Ŝ(t)} is from the Equation 25.
Few problems may arise with this procedure, one being the symmetry of the
confidence interval. When Ŝ(t) is close to zero or unity, the symmetric con-
fidence limits can lie outside the interval (0, 1), making them inappropriate.
A simple solution is to replace any limit exceeding unity by 1.0 and any limit
below zero by 0.0.
Alternatively, Ŝ(t) can be transformed to a value in the range (−∞, ∞). A
confidence interval is obtained for the transformed value and back-transformed
to give a confidence interval for S(t). Possible transformations are the logistic
transformation, log [S(t)/{1− S(t)}], and the complementary log-log transfor-
mation, log {− log S(t)}. Now, the variance of the latter quantity is obtained
from the Equation 23 by using the general result in the Equation 21:
var{log (−X)} ≈ 1
X2
var(X).
Setting X = log Ŝ(t) gives
var
{
log[− log Ŝ(t)]
}
≈ 1
{log ˆS(t)}
k∑
j=1
dj
n′j(n′j − dj)
. (27)
Now the square root of the Equation 27 is the standard error of
log {− log S(t)}, which leads to a 100(1 − α)% approximate confidence
interval limits for S(t) of the form
Ŝ(t)exp[±zα/2×se{log[− log Ŝ(t)]}]
Another problem is that the variance of Ŝ(t), obtained using the Greenwood’s
formula, can underestimate the actual variance, when Ŝ(t) is close to unity
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or zero in the tails of the distribution of the survival times. In these circum-
stances, an alternative expression for the standard error of Ŝ(t) may be used,
but the Greenwood estimate is recommended for general use (Collett 2015).
2.6 Estimating the median and percentiles of survival
times
In this section a method for estimating the median, and other percentiles, of
survival times is presented. The theory in this section is based on Collett
(2015), Gehan (1969), Seppä (2012) and Seppä et al. (2016).
The median survival time is often the preferred summary measure of the lo-
cation of the distribution of survival times. The distribution of survival times
tends to be positively skewed and obtaining the mean survival time, more often
than not, requires an extrapolation of the survival times. The median survival
time is obtained from the estimated survival function, it is the time beyond
which 50 % of the individuals in the population under study are expected to
survive. This is the value t(50) such that S{t(50)} = 0.5. Since the life table
estimate of the survival function is a non-parametric step-function, it is rare to
realise the exact value. Instead, the estimated median survival time, t̂(50), is
the shortest observed survival time for which the estimated survival function
is less than 0.5:
t̂(50) = min {t | Ŝ(t) < 0.5}.
In a situation where the estimated survival function is exactly equal to 0.5,
for tj−1 ≤ t < tj, the median is taken at the halfway point of that interval,
(tj−1+tj)/2. Without any censored survival times in the sample, the estimated
median is the shortest survival time beyond which 50 % of the individuals
survive.
A similar procedure can be used to estimate other percentiles of the distribution
of survival times: the pth percentile is the value t(p), such that S{t(p)} =
1− (p/100) for p ∈ [0, 100]. E.g. the 10th and the 90th percentiles are
S{t(10)} = 0.90 and S{t(90)} = 0.10.
With the estimated survival function, the estimated pth percentile is the small-
est observed survival time, t̂(p), such that Ŝ{t̂(p)} < 1 − (p/100). In some
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cases, the estimated survival function is greater than 0.5 for all values of t and
the median survival time can’t be estimated. Then it is natural to summarise
the distribution of survival times through other percentiles.
The variance of the estimated median and percentiles can be approximated by
using the result in the Equation 21:
var[Ŝ{t̂(p)}] ≈
(
dŜ{t̂(p)}
dt̂(p)
)2
var{t̂(p)}, (28)
where
−dŜ{t̂(p)}
dt̂(p)
= f̂{t̂(p)}
is an estimate of the probability density function of survival times at t̂(p). Now,
rearranging the Equation 28 gives the approximated variance of the estimated
percentile p:
var{t̂(p)} ≈
(
1
f̂{t̂(p)}
)2
var[Ŝ{t̂(p)}].
Thus, the standard error of the estimated pth percentile, is given by
se{t̂(p)} ≈ 1
f̂{t̂(p)}
se[Ŝ{t̂(p)}]. (29)
The Greenwood’s formula given in the Equation 25 is used to find se[Ŝ{t̂(p)}]
and
f̂{t̂(p)} = Ŝ{û(p)} − Ŝ{l̂(p)}
l̂(p)− û(p)
,
where
û(p) = max
{
t|Ŝ(t) ≥ 1− p100 + ε
}
,
and
l̂(p) = min
{
t|Ŝ(t) ≤ 1− p100 − ε
}
,
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for small values of ε. Usually, ε = 0.05 is satisfactory, but greater values are
needed if û(p) and l̂(p) turn out to be equal. Once se{t̂(p)} has been found, a
100(1− α)% confidence interval for t̂(p) has limits of
t̂(p)± zα/2 × se{t̂(p)}.
This interval estimate is only approximate, in the sense that the probability
that the true percentile lies within the interval may not be exactly 1−α. Other
methods have been proposed for constructing the confidence interval for the
median and percentiles, but will not be presented in this thesis (Collett 2015).
2.7 Estimating net survival
In this section, two methods for estimating net survival will be presented,
the Pohar Perme (PP) and the Ederer II (E2) method. Their variances and a
method for age-standardisation are also given. In this thesis, other well-known
methods are left out (e.g. Ederer I and Hakulinen), since the two presented
methods have been recently recommended (Seppä et al. 2016). Only life table
estimators are given. The theory in this section is based on Seppä et al. (2016).
Ederer I and Hakulinen methods of estimating net survival are described in
Dickman and Coviello (2015).
The Pohar Perme estimator is based on the weighted individual-level observa-
tions of nj, dj and cj:
nwj =
n∑
i=1
nij
SPij
, dwj =
n∑
i=1
dij
SPij
and cwj =
n∑
i=1
cij
SPij
, (30)
where SPij is the patient-specific cumulative expected survival probability,
calculated at the mid point of the interval j, tj = (tj−1− tj)/2. It is calculated
with the interval-specific expected survival probabilities p∗ij (j = 1, . . . , J) from
national population life tables:
SPik =
J−1∏
j=1
p∗ij
√
p∗iJ ,
where
√
p∗iJ , the conditional survival probability, is assumed to be equal for
the first and the second half of the Jth interval.
The Pohar Perme etsimator of the net survival probability is
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ŜPPE (t) =
k∏
j=1
(
1−
dwj
nwj − cwj /2
)/
exp
(
−
d̃∗wj
nwj − cwj /2− dwj /2
)
, (31)
for tj−1 ≤ t < tj, j = 1, 2, . . . , J , where d̃∗wj is the expected number of deaths
in the interval j weighted by the cumulative expected survival probabilities:
d̃∗wj =
n∑
i=1
− log (p∗ij)(nij − cij/2− dij/2)
SPij
.
Note that for an individual i in the interval j the follow-up time is ∆j =
tj − tj−1, if the individual is alive at the end of the interval. If the individual
dies or is censored during the interval, the follow-up time is half of the length
of the interval ∆j/2.
The estimated variance of the Pohar Perme estimator is
v̂ar
[
ŜPPE (t)
]
=
[
ŜPPE (t)
]2 k∑
j=1
∑n
i=1 dij/S
2
Pij(
nwj − cwj /2− dwj /2
)2 .
Here, the weighted number of person-years in the interval j is approximated
with
(
nwj − cwj /2− dwj /2
)
∆j. Thus the estimator is modified from the esti-
mated variance of the Pohar Perme estimator of net survival derived with the
hazard approach (Seppä et al. 2016).
The Ederer II estimator is a special case of the Pohar Perme estimator in the
Equation 31. Here the same interval-specific weight is used for each individual,
SPij = SPj, for all i:
ŜE2E (t) =
k∏
j=1
(
1− dj
nj − cj/2
)/
exp
(
−
d̃∗j
nj − cj/2− dj/2
)
,
where
d̃∗j =
n∑
i=1
− log (p∗ij) (nij − cij/2− dij/2)
is the expected number of deaths in the interval j. The estimated variance is
v̂ar
[
ŜE2E (t)
]
=
[
ŜE2E (t)
]2 k∑
j=1
dj
(nj − cj/2) (nj − cj/2− dj)
.
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This estimator is based on the Greenwood’s formula on the variance of the
cumulative observed survival proportion (Seppä et al. 2016). In a case that
all individuals that enter an interval, die during the interval, both of these
point estimators and their variances become zero.
Internal age standardisation is a common practise when estimating net sur-
vival, because net survival, and the background mortality of the general pop-
ulation usually depend on the same demographic factors. Old patients have a
higher risk of dying from causes other than cancer, thus their contribution to
long-term net survival is underweighted without age standardisation. The age
distribution of patients at the time of diagnosis is used as the standard. In
the life table method age standardisation is relevant for both of the presented
estimates, for it also controls for the effect of informative censoring, that is
due to the heterogenity in the potential follow-up times. Additionally, for the
Pohar Perme estimator, age standardisation adjusts for the differences in the
age distribution between individuals diagnosed prior to, and within, the period
window.
Individuals are divided into, say M , age groups according to their age at time
of diagnosis. Now, let n1(m) be the number of individuals alive and under
observation at the beginning of the follow-up in age group m. Both of the
presented estimators, PP an E2, are weighted averages of the pertinent age-
specific estimators ŜE(t,m), m = 1, 2, . . . ,M :
ŜE(t) =
1
n1
M∑
m=1
n1(m)ŜE(t,m).
The estimated variance of the age-standardised estimate of net survival:
v̂ar
[
ŜE(t)
]
= 1
n21
M∑
m=1
[n1(m)]2v̂ar
[
ŜE(t,m)
]
.
The estimate is unavailable in the last follow-up time interval, if the follow-up
is incomplete and some individuals in an age group survive over the interval.
The confidence interval of net survival can be approximated, for each estimator
with its variance, on the logarithmic scale:
exp
{
log
(
ŜE(t)
)
± zα/2 × v̂ar
[
log
(
ŜE(t)
)]}
,
where the variance of the natural logarithm of the net survival probability is
approximated with the delta method:
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v̂ar
[
log
(
ŜE(t)
)]
=
[
ŜE(t)
]−2
v̂ar
[
ŜE(t)
]
,
and zα/2 is the 100(1− α/2) percentile point of the standard normal distribu-
tion.
2.8 Computational tools
To produce the results of this thesis, the statistical computing language R
version 3.6.1 (R Core Team 2019) was used in an integrated development
environment RStudio version 1.1.456 (RStudio Team 2016).
The Lexis function from the Epi package (Carstensen et al. 2019) was used
to transform the follow-up times into a Lexis type object, which is needed to
estimate the survival time functions. The survtab function from the popEpi
package (Miettinen and Rantanen 2019) was used to estimate the survival
functions presented.
The survtab function estimates the observed survival as well as the Ederer
II and the Pohar Perme estimators of net survival. The life table methods
of estimation, described in Section 2, were used. Breaks in the life table
intervals were set at one year apart after diagnosis. The complementary log-
log transformation and the delta method are used to calculate the confidence
interval for the survival function by default (Miettinen and Rantanen 2019).
To estimate the expected survival proportions, knowledge about the expected
hazard levels in the population is required. This information was provided
in the popmort dataset, included in the popEpi package, which contains the
population mortality rates in Finland in 1951 - 2013 in 101 one-year age groups
by gender (Miettinen and Rantanen 2019).
The package colorspace (Zeileis et al. 2019) was used for clear and colour
blind friendly visualisation of the results, as suggested by Zeileis, Hornik, and
Murrell (2009).
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3 Material
The data used in this thesis were provided by Finnish Cancer Registry con-
taining all cases of cancer of the oral cavity diagnosed in Finland between 1994
and 2013, a total of 4211 cases. Out of all cases, 201 were diagnosed only in
autopsy and were excluded from the analyses, thus 4010 cases were used in
the analyses. The patients in the data were born between 1902 and 1998 and
the follow-up period extended through 2014.
The data consist of cancers with their primary location in the oral cavity, which
consists of the tongue, tonsils, gums, the floor and the palate of mouth, the
uvula, the retromolar area, the vestibule of mouth and an otherwise unspeci-
fied mouth area. Cancers of the lip and the pharynx area were not included.
In Table 1 are listed all specific locations, ICD-O-3 codes (World Health Or-
ganization 2013) and frequencies.
The data are virtually free of missing observations of cancer cases, since all
health organizations in Finland have a statutory obligation to provide infor-
mation about every detected case or strong suspicion of cancer to the Finnish
Cancer Registry. The coverage of all cancer cases in Finland is reported to
be about 96 % (Finnish Cancer Registry 2020). The Finnish Cancer Reg-
istry receives data about cancer in Finland from institutions, e.g. hospitals,
that provide treatment for cancer patients, healthcare professionals, pathol-
ogy laboratories, and Statistics Finland provides data about causes of death.
Information is received from multiple sources, and data from clinical notifica-
tions are considered to be the most accurate, if conflicts appear. The database
of the registry is continuously updated and corrected, if errors are detected.
(Finnish Cancer Registry 2020)
There are a few censored observations in the data, those are patients that have
emigrated during the follow-up and patients that are still alive at the end of
2014, when the follow-up ended.
Few changes were done to the original data. The stage of cancer is originally
provided as a variable with seven levels. In the analyses of this thesis “Local”
and “Unknown” levels were kept as they are, but the remaining levels were
combined into a “Spread” level. The status when patients exit the study was
originally provided as a variable with four levels, but was combined in the
analyses into two levels: dead with observed survival time or censored without
observed survival time.
Birthdays of the patients were provided exactly, but for the date of diagnosis
and the date of death or emigration only the month and the year are known.
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Since the data were lacking these exact dates, the actuarial assumption was
used: the date of diagnosis, and the date of death or emigration, was set to
the middle point of the given month. For patients that were alive at the end
of the data collection, the exit time was set to the closing date of the follow-up
period.
Some patients in the data only had a record of the year of diagnosis. In these
cases the actuarial assumption was extended and the date of diagnosis was
set to the middle point of the year. The patients who did not have an exact
record of the month of diagnosis, and death had occurred before the middle
point of the same year, the month of diagnosis was set so, that the patient
was under follow-up for half of the time they were alive that year. Patiens
who were diagnosed and had died in the same month were set to have had a
survival time of approximately two weeks.
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Code Description N
C02.0 Dorsal surface of tongue, NOS 13
C02.1 Border of tongue 466
C02.2 Ventral surface of tongue, NOS 35
C02.3 Anterior 2/3 of tongue, NOS 16
C02.4 Lingual tonsil 12
C02.8 Overlapping lesion of tongue 6
C02.9 Tongue, NOS 1243
C03.0 Upper gum 63
C03.1 Lower gum 153
C03.9 Gum, NOS 31
C04.0 Anterior floor of mouth 50
C04.1 Lateral floor of mouth 20
C04.8 Overlapping lesion of floor of mouth 5
C04.9 Floor of mouth, NOS 820
C05.0 Hard palate 30
C05.1 Soft palate, NOS 52
C05.2 Uvula 12
C05.8 Overlapping lesion of palate 3
C05.9 Palate, NOS 61
C06.0 Cheek mucosa 152
C06.1 Vestibule of mouth 4
C06.2 Retromolar area 31
C06.8 Overlapping lesion of other and unspecified parts of mouth 5
C06.9 Mouth, NOS 726
Total 4010
Table 1: All topography codes in the data and their frequencies
Abbrevations: NOS – Not Otherwise Specified
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4 Results
In this chapter the baseline characteristics and the results of the survival anal-
yses are presented. The survival analyses are stratified by patients’ sex, age,
stage of cancer and calendar time at the time of diagnosis. The Ederer II
estimator of net survival was used in the analyses. At the end of this chapter,
the Pohar Perme and the Ederer II estimators of net survival are compared.
4.1 Baseline characteristics
In Table 2, the distribution of the cases of cancer used in the analyses of this
thesis are presented by key variables. There were more men in the data, 52
%. Throughout the analyses sex is an important variable that is adjusted for.
Men (%) Women (%) Total (%)
Age at diagnosis
0-44 years 170 (8) 137 (7) 307 (8)
45-54 years 430 (21) 213 (11) 643 (16)
55-64 years 649 (31) 373 (19) 1022 (25)
65-74 years 505 (24) 458 (24) 963 (24)
75-100 years 340 (16) 735 (38) 1075 (27)
Cancer stage
Local 813 (39) 867 (45) 1680 (42)
Spread 842 (40) 557 (29) 1399 (35)
Unknown 439 (21) 492 (26) 931 (23)
Calendar year of diagnosis
1994-1998 359 (17) 377 (20) 736 (18)
1999-2003 468 (22) 395 (21) 863 (22)
2004-2008 544 (26) 529 (28) 1073 (27)
2009-2013 723 (35) 615 (32) 1338 (33)
Total (%) 2094 (52) 1916 (48) 4010 (100)
Table 2: Diagnosed cases of cancer of the oral cavity in Finland in 1994-2013
by key variables.
The first variable in Table 2 is the patient’s age at the time of diagnosis. These
age groups are generally recommended, i.e. by Seppä et al. (2016). There was a
considerable difference in the distribution of ages between sexes. More women
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were diagnosed at the older ages. Most women were diagnosed when they were
75-100 years old. The largest age group for men was 55-64 years. More men
than women were diagnosed at younger ages, 45-54 years and 55-64 years. In
the whole population these effects were not present, all age groups after the
age of 55 years had an approximately similar number of diagnosed cases of
cancers of the oral cavity.
The second variable in Table 2 is the stage of cancer at the time of diagnosis.
In the population, most cases were diagnosed as “Local”, 42 %, while 35 % of
the cases were diagnosed as “Spread”. Between men and women, there was a
difference of 11 percentage points in the cases of cancer that were diagnosed as
“Spread”. The majority of cancers for men, 40 %, were diagnosed as “Spread”.
The third variable in Table 2 is the calendar year at the time of diagnosis.
The period 1994-2013, when the patients were diagnosed, was divided into
four five-year periods. The number of diagnosed cases of cancer is larger in
the later five-year periods. There was little difference between men and women
within these periods.
4.2 Overall survival
In Figure 1, the observed survival curve and the curve for the Ederer II esti-
mator of net survival are presented, separately for men and women. In Table
3, values of both estimators are presented at five and ten years after diagnosis.
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Figure 1: Comparison between the observed survival proportion and the Ed-
erer II estimator of net survival. The red line corresponds to the observed
survival proportion and the blue line corresponds to the Ederer II estimator.
The dashed lines show the 95 % confidence intervals.
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Time Method Sex
Men (SE) Women (SE)
5 years Observed 52 (1.2) 57 (1.2)
Relative 59 (1.3) 67 (1.4)
10 years Observed 36 (1.2) 42 (1.3)
Relative 47 (1.6) 59 (1.8)
Table 3: The observed survival proportions per 100 and the Ederer II estima-
tors of net survival per 100 at five and ten years after diagnosis.
The estimated net survival proportion was higher than the observed survival
proportion at five and ten years after diagnosis when stratified by sex. At the
same time, women had a higher observed and relative five-year and ten-year
survival than men. When the analysis was stratified by sex the standard error
of the estimates was reasonably low for both estimates for the whole follow-up
period of 20 years.
As seen in Table 2, cancer affected older people more frequently, while older
people in the population simultaneously have a higher overall hazard of death
from all sources. This higher hazard weighs the hazard of death from cancer
down, thus the estimated net survival was higher than the observed survival.
As mentioned in Section 4.1, there were more women diagnosed at older age
than there were men. The difference between the estimated net survival and
the observed survival was bigger for women than for men.
In Table 4, the median survival times for men and women are presented.
The observed median survival time had a stable estimate for both men and
women in this sample. Women had approximately two years longer median
survival time than men. The median survival time estimated with the Ederer
II estimator was less precise, especially that for women had a large standard
error.
Method Sex
Men (SE) Women (SE)
Observed 6 (0.3) 8 (0.4)
Relative 10 (0.8) 17 (2.7)
Table 4: Median survival times (years) calculated with the observed and the
relative survival estimates.
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4.3 Survival by age at the time of diagnosis
In Figure 2, the observed and the relative survival curves are presented, strat-
ified by patient’s age at the time of diagnosis. In Table 5, the estimates of
the observed and the relative survival function at 5 years after diagnosis are
presented in the different age groups.
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Figure 2: Comparison between the observed survival proportion and the Ed-
erer II estimator of net survival in five age groups. Plots on the left show
observed survival, while plots on the right show relative survival. Correspond-
ing colours and age groups go sequentially from the lightest blue referring to
the youngest age group to the darkest blue for the oldest age group. The age
groups are 0-44 years, 45-54 years, 55-64 years, 65-74 years and 75-100 years.
The five-year survival estimates were similar in the age groups 45-54 years
and 55-64 years for both sexes. Otherwise the older age groups had a lower
estimated survival. A clear difference between the two estimates, within an
age group, was seen only in the two oldest age groups for both sexes.
The Ederer II estimator started behaving illogically at 12 to 15 years after
diagnosis in the oldest age group for both sexes. The relative survival curve
of the age group 65-74 years for men had a rapid decrease, and a rising spike
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Age
(years) Method
Sex
Men (SE) Women (SE)
0-44 Observed 76 (3.4) 83 (3.3)
Relative 76 (3.4) 83 (3.3)
45-54 Observed 58 (2.5) 73 (3.1)
Relative 60 (2.6) 75 (3.1)
55-64 Observed 57 (2.1) 73 (2.4)
Relative 61 (2.2) 76 (2.5)
65-74 Observed 47 (2.4) 66 (2.3)
Relative 55 (2.8) 72 (2.5)
75-100 Observed 30 (2.7) 34 (1.8)
Relative 50 (4.1) 55 (2.7)
Table 5: The observed survival proportions per 100 and the Ederer II esti-
mators of net survival per 100 at five years after diagnosis, stratified by age
(years) at the time of diagnosis.
for women, at around 15 to 16 years after diagnosis. The observed survival
was close to zero for patients in the oldest age group for both sexes after 13
to 15 years after diagnosis. For men the observed survival dropped to a very
low level also in the age group 65-74 years at around 17 years after diagnosis.
In Table 6, the numbers of patients alive in the two oldest age groups at 10, 15
and 20 years after diagnosis are presented. There were only few observations
after 15 years of follow-up. The last man in the oldest age group had a censored
survival time after 19 years of follow-up. If there were only few patients left
in a particular group and no deaths were observed in an interval, the relative
survival started behaving illogically, i.e. jumping up and down.
When stratified by age, the relative survival indicated smaller differences in
survival between the age groups, than the observed survival. That is, un-
til about ten years after diagnosis, when the stratified group sizes were still
sufficient.
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Age
(years) Time
Sex
Men Women
65-74 10 years 68 123
15 years 14 33
20 years 1 7
75-100 10 years 20 58
15 years 3 7
20 years 0 1
Table 6: Number of patients alive in the two oldest age groups at 10, 15 and
20 years after diagnosis.
4.4 Survival by the stage of cancer at the time of diag-
nosis
In Figure 3, the observed and the relative survival curves are presented, strat-
ified by the stage of cancer at the time of diagnosis. In Table 7, the five-year
survival estimates are presented by the stage of cancer and sex for both ob-
served and relative survival.
The estimated survival dropped below 0.5 only two to three years after diag-
nosis for both sexes, if the cancer was diagnosed as “Spread”. The relative
survival curve seemed to be shifted more for the “Local” cancer cases in the
later time points than for the “Spread” cancer cases.
Stage Method Sex
Men (SE) Women (SE)
Local Observed 67 (1.7) 70 (1.6)
Relative 77 (1.9) 81 (1.8)
Spread Observed 36 (1.8) 36 (2.1)
Relative 41 (1.9) 42 (2.4)
Unknown Observed 52 (2.7) 59 (2.5)
Relative 60 (3.1) 72 (2.9)
Table 7: The observed survival proportions per 100 and the Ederer II estima-
tors of net survival per 100 at five years after diagnosis stratified by the stage
of cancer at the time of diagnosis.
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It was expected that cases of cancer that are diagnosed as “Local” would
have a better estimated survival than cases diagnosed as “Spread”, and at
five years after diagnosis, the difference was clear. Survival for patients with
cancer diagnosed with an “Unknown” stage was between survival of cancers
diagnosed as “Local” and “Spread”.
There was little difference between the survival of men and women, when
stratified by the stage of cancer at the time of diagnosis. Especially patients
with cancer diagnosed as “Spread” had a similarly low survival, regardless of
their sex. The difference between men and women with cancer diagnosed as
“Local” was also small.
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Figure 3: Comparison between the observed survival proportion and the Ed-
erer II estimator of net survival by cancer stage at diagnosis. Plots on the
left show observed survival, while plots on the right show relative survival.
Corresponding colours and cancer stage: “Local” blue, “Spread” red and “Un-
known” gray.
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4.5 Survival by the calendar year at the time of diag-
nosis
In Figure 4, the observed and the relative survival curves are presented for
men and women, stratified by the calendar year at the time of diagnosis.
Patients were grouped into those diagnosed between 1994-2003, and those
diagnosed between 2004-2013. Here survival curves are presented only for the
first ten years of follow-up, since that was the maximum follow-up time for
the latter group. In Table 8, the five-year and the ten-year survival estimates
are presented for both sexes and groups.
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Figure 4: Comparison between observed survival proportion and the Ederer
II estimator of net survival by the calendar year of diagnosis. Plots on the
left show observed survival, while plots on the right show relative survival.
Corresponding colours and calendar years: 1994-2003 blue, 2004-2013 red.
There was little difference in the ten-year estimates within any grouping. In-
stead some difference was found in the five-year estimates of survival. Accord-
ingly the survival from cancer of the oral cavity had not changed noticeably
over time.
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Calendar
time Time Method
Sex
Men (SE) Women (SE)
1994-2003 5 years Observed 49 (1.7) 56 (1.8)
Relative 56 (2.0) 66 (2.1)
10 years Observed 35 (1.7) 41 (1.8)
Relative 46 (2.1) 58 (2.5)
2004-2013 5 years Observed 54 (1.6) 58 (1.6)
Relative 62 (1.7) 68 (1.8)
10 years Observed 34 (2.6) 44 (2.2)
Relative 45 (3.2) 61 (2.9)
Table 8: The observed survival proportions per 100 and the Ederer II estima-
tors of net survival per 100 at five and ten years after diagnosis stratified by
the calendar year at the time of diagnosis.
4.6 Comparison of the Pohar Perme and the Ederer II
estimators of net survival
In Figure 5, the Ederer II and the Pohar Perme estimators of net survival are
compared in three different age groups introduced in Table 2. As mentioned
in Section 2.7, these two methods have been recommended by Seppä et al.
(2016). In Table 9 the estimates of net survival at five and ten years after
diagnosis are presented for both estimators in the same age groups.
The Ederer II and the Pohar Perme estimators appeared to perform similarly
up to five years in all three age groups, but with longer follow-up times the
Ederer II estimator had a lower standard error than the Pohar Perme estima-
tor. The difference was seen in Figure 5, in the age group 55-64 years when the
follow-up time was extended up to 20 years. This difference in the precision
of the estimators was clear in the oldest age group already at 10 years after
diagnosis, although both estimators tend to become very unstable at the later
time points. A similar effect of unstable estimates was already seen in Figure
2, due to a low number of observations in the older age groups at the later
follow-up times, as seen in Table 6.
Furthermore, in Figure 6, the age standardised survival curves for the Ederer
II and the Pohar Perme estimators are presented. The estimators performed
similarly for the whole follow-up period. After ten years of follow-up, the
standard error of the Pohar Perme estimator was larger than the standard
error of the Ederer II estimator. This is caused by the fact that the Pohar
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Both estimators performed similarly, when the five-year survival was esti-
mated. The Ederer II estimator had a lower standard error than the Pohar
Perme estimator at the later time points, thus the Ederer II estimator for the
net survival probability was used in the descriptive analyses of this thesis.
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Figure 6: Comparison between the age standardised Ederer II and Pohar
Perme estimators. Plot on the left shows the survival of men, while plot on
the right shows the survival of women. The red line corresponds to the Pohar
Perme estimator and the blue line corresponds to the Ederer II estimator. The
dashed lines show the 95 % confidence intervals.
Age
group Time Sex
Estimator
Ederer II (SE) Pohar Perme (SE)
0-44 years 5 years Men 76 (3.4) 76 (3.3)
Women 83 (3.3) 83 (3.2)
10 years Men 70 (4.1) 70 (4.1)
Women 78 (1.0) 78 (3.9)
55-64 years 5 years Men 61 (2.2) 61 (2.2)
Women 76 (2.5) 76 (2.4)
10 years Men 48 (2.8) 48 (3.0)
Women 68 (3.2) 68 (3.3)
75-100 years 5 years Men 50 (4.1) 48 (5.3)
Women 55 (2.7) 55 (3.2)
10 years Men 35 (6.3) 33 (17.5)
Women 45 (4.6) 45 (11.9)
Table 9: The Ederer II and the Pohar Perme estimators of net survival per
100 at five and ten years after diagnosis.
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5 Discussion
5.1 The concept of net survival
Net survival is a hypothetical quantity which, in this thesis, was mainly es-
timated using the method of relative survival. Relative survival is especially
suitable when large amounts of data are available, which was the case with the
national register data used in this population-based study (Henson and Ries
1995). In the literature, there seems to be some inconsistency in the definition
and the interpretation of the survival concepts (Ellis et al. 2014), e.g. some
use the term net survival as a synonym for cause-specific survival, while it
can be also used like the term net probability in the theory of competing risks
(Dickman et al. 2004).
A relative survival ratio is defined as the ratio of the observed survival propor-
tion in the patient group, to the expected survival proportion in a similar group
at the beginning of the interval with respect to factors affecting mortality, ex-
cept the disease under study. It is sometimes interpreted as the proportion of
patients alive at the end of an interval to the patients alive at the beginning
of the interval, provided that patients are only dying because of the interest-
ing disease. This interpretation gives basis for drawing the relative survival
curves. (Hakulinen 1977)
The relative survival ratio and the net survival proportion were thought to be
the same quantity until quite recently, with the former serving as an estimate
of the latter, although these two can be very different in practice. The relative
survival ratio has a clear interpretation in the real world (Pohar Perme, Stare,
and Estève 2012), but is often less desirable than the net survival proportion
because it is stronly dependent on the population mortality trends. Though
the concept of net survival is commonly used, it must be kept in mind that it
is not a real world measure. (Rebolj Kodre and Pohar Perme 2013)
As mentioned in Section 2.3 the interpretation of net survival, as the survival
probability in the hypothetical situation where patients can only die of can-
cer, requires strong assumptions about the independency of competing risks
(Rebolj Kodre and Pohar Perme 2013). This assumption can not be tested,
and generally the assumption can be taken to be invalid. Hence the observed
net survival does not have a proper probability interpretation (Seppä 2012),
and the interpretation of net survival as a hypothetical probability of dying of
cancer is usually not even of interest (Rebolj Kodre and Pohar Perme 2013).
Two different estimators were compared in Section 4.6. Both estimators of net
39
survival, the Pohar Perme and the Ederer II, performed similarly when a short
term net survival was estimated, e.g. five-year survival, and a large quantity
of data was available. When a long term net survival was estimated, and less
data were available, the Pohar Perme estimator was more prone to error. Even
if the Ederer II estimate might be too optimistic about it’s accuracy, it was
used in the descriptive analyses, because survival up to 20 years after diagnosis
was of interest in this thesis. Both estimators also showed a rising survival
curve at the later time points, which cannot be interpreted in a meaningful
way. Similar results, about the accuracy of these two estimators, were also
reported earlier in Seppä, Hakulinen, and Pokhrel (2015) and Seppä et al.
(2016).
5.2 Results of the survival analysis
The patients’ age and stage of cancer at the time of diagnosis were used to
stratify the analyses. These factors clearly affected the survival of the patients
heavily. Patient’s age and stage of cancer at the time of diagnosis are well
known factors that affect the prognosis of cancer (Joensuu et al. 2013).
There was little or no difference found between the observed and the relative
survival estimates in the two youngest age groups. A clear difference between
the two estimators was only seen in the two oldest age groups. Older patients
have a lower expected survival than younger patients, in the general popula-
tion, which elevates their relative survival compared to observed survival.
The importance of the stage of cancer at the time of diagnosis as a prognostic
factor was clearly seen. Patients diagnosed with cancer that had already spread
at the time of diagnosis had their estimated survival almost halved, compared
to those who were diagnosed with cancer that was local in the oral cavity.
There was less difference in the estimated survival between sexes when the
analyses were stratified by the stage of cancer.
There were more individuals diagnosed with cancer in the calendar period
2004-2013 than in the previous ten-year calendar period, 1994-2003. The in-
crease in cancer cases might be due to many reasons. The fact that people
tend to live longer is mentioned as a primary reason by Finnish Cancer Reg-
istry (2020). NORDCAN (Danckert et al. 2020; Engholm et al. 2010) also
estimates the number of new cases per year rising annually in the latest ten
years by 2.0 % for both sexes, and the number of deaths per year due to cancer
of the oral cavity by 2.2 % and 2.6 % for men and women respectively. The
relative five-year survival per 100 in 2012-2016 was 60 [55-64] and 71 [67-75]
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for men and women respectively. Similarly, rising numbers of oral cancer cases
were reported by The SEER Cancer Statistics Review (CSR) (Howlader et al.
2020) and by Weir et al. (2015) in the United States.
The estimated five-year relative survival ratio was similar in both ten-year
calendar periods in the analyses of this thesis. The reported relative survival
by NORDCAN (Danckert et al. 2020; Engholm et al. 2010) was also similar.
Even if the number of cancer cases is rising, the survival from cancer of the
oral cavity has stayed similar over time. The SEER CSR reports a slow, but
steady, rising trend in the five-year relative survival ratio of oral cancer patients
(Howlader et al. 2020). Similar trend in Finland cannot be deduced from the
results of this thesis.
Men and women had different distributions of age in the diagnosed cases of
cancer of the oral cavity. Also, proportionally more men were diagnosed with
cancer that had spread at the time of diagnosis, compared to women. As
said before, patient’s age and the stage of cancer at the time of diagnosis are
important factors for the expected survival from cancer. Overall, men have
lower five-year and ten-year survival estimates than women.
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